Royalty Payments for Licensed Products. Subject to the other terms of this ARTICLE 8, during the Royalty Term, Astellas shall make quarterly non-refundable, non-creditable royalty payments to Pandion on the Net Sales of each Licensed Product at the applicable royalty rate set forth below. Net Sales shall be aggregated on a Licensed Compound-by-Licensed Compound basis across all Indications in a given calendar year. Annual Net Sales of all Licensed Products containing the same Licensed Compound in a given calendar year Royalty Rate
Royalty Payments for Licensed Products. (a) As further consideration for Licensor’s grant of the rights and licenses to Viking hereunder, Viking shall, during each applicable Royalty Term, pay to Metabasis and/or Ligand a royalty on aggregate annual worldwide Net Sales of Licensed Products by Viking and its Affiliates and Sublicensees, as and at the percentage rates set forth on SCHEDULE 7.
Royalty Payments for Licensed Products. (a) As further consideration for Licensor’s grant of the rights and licenses to Merck hereunder, Merck shall, during the Royalty Term, pay to Licensor a non-refundable royalty on aggregate annual Net Sales of the Licensed Product for each Calendar Year, on a Licensed Product-by-Licensed Product and a country-by-country basis at the percentage rates set forth below (subject to Articles 6.5 (c), 6.6, and 6.7 below): Annual Net Sales of Licensed Product per Calendar Year (in U.S. Dollars) in the US if no Co-commercialization occurs Incremental Royalty Rate [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] [* * *] Annual ROW Net Sales of Licensed Product per Calendar Year (in U.S. Dollars) Incremental Royalty Rate [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] [* * *] [ ***] If the Adjustment Trigger occurs, then the royalty rates shall be as follows: [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] By way of illustration, [* * *]: [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***] [* * *] [***]
Royalty Payments for Licensed Products. If and only if Licensee exercises the Option, the following royalty payments shall be due and payable on the terms set forth herein this Section 6.4.
Royalty Payments for Licensed Products. (a) As further consideration for Licensor’s grant of the rights and licenses to Merck hereunder, Merck shall, during each applicable Royalty Term, pay to Licensor a royalty on aggregate annual worldwide Net Sales [***] for each [***], on [***] at the percentage rates set forth below (subject to Sections 5.4(b), 5.5, and 5.6 below): Annual worldwide Net Sales of [***] [***] Royalty Rate [***] [ ***] % [***] [ ***] % [***] [ ***] % *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. These royalty rates shall be decreased by [***], for Net Sales of any Licensed Product in any country in which a Valid Claim does not exist at the time the payment of royalties is due; and such [***] decrease shall persist for such Licensed Product in such country until [***]. For the avoidance of doubt, if for any Licensed Product in any country a Valid Claim does not exist at the time the payment of royalties is due, [***], in such country ([***]), [***]. [***] By way of illustration, assume in a [***] that (i) aggregate worldwide annual Net Sales [***] in U.S. Dollars total USD [***] and (ii) no adjustments or deductions to payments under this Article 5 apply. The total royalties due and payable by Merck to Licensor for such Net Sales would be [***] U.S. Dollars (USD[***]), calculated as follows: [***] [***] [***] Total Royalty = USD [***]
Royalty Payments for Licensed Products. Licensee shall pay to the University within thirty (30) days after the end of each calendar quarter, during the term of the license of paragraph 2.02, the following royalties, based on the Net Sales of all Licensed Products sold by Licensee and its Affiliates.
Royalty Payments for Licensed Products. (a) With respect to Net Sales of all Licensed Products during the applicable Royalty Term: as further consideration for Licensor’s grant of the rights and licenses to AUM hereunder, AUM shall pay to Licensor royalties based on the aggregate annual Net Sales of all such Licensed Products by AUM and its Affiliates and Sublicensees within the Territory (but excluding Net Sales of a given Licensed Product after its applicable Royalty Term) at the rate shown in the table below:
Royalty Payments for Licensed Products. (a) As further consideration for Lpath’s performance of its obligations under this Agreement and its grant of the rights and licenses to Merck hereunder, Merck shall, during the Royalty Term (on a Licensed Product-by Licensed Product and a country-by-country basis), pay to Lpath running royalties on Net Sales of Licensed Products, at the percentage rates set forth below determined based on Net Sales of all Licensed Products in the Territory, (subject to Sections 5.10(a) through (c) below): *** *** *** *** *** *** *** *** *** *** For clarity, the applicable royalty rate(s) for the purposes of calculating the royalties payable by Merck shall be determined based upon the aggregate Net Sales of all Licensed Products sold in ***. By way of illustration, assume in *** that (i) worldwide *** aggregate Net Sales of all Licensed Products were ***, and (ii) ***. The total royalties due and payable by Merck to Lpath for such Net Sales would be ***
Royalty Payments for Licensed Products. As further consideration for Delta’s grant of the rights and licenses to Ares hereunder, Xxxx shall, during the Royalty Term, pay to Delta a non-refundable royalty on aggregate annual Net Sales of the Licensed Product for each Calendar Year, on a Licensed Product-by-Licensed Product and a country-by-country basis at a rate of [***] of Net Sales. For purposes of determining whether a royalty threshold has been attained, only Net Sales that are subject to a royalty payment shall be included in the total amount of Net Sales and any Net Sales that are not subject to a royalty payment shall be excluded (e.g. it would not include Net Sales for a certain Licensed Product in a certain country if the Royalty Term has ended with respect to such Licensed Product in such country). In addition, in no event shall the mere manufacture (i.e., absent a sale) of the Licensed Product give rise to *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
Royalty Payments for Licensed Products. (a) With respect to Net Sales of Licensed Products which are Covered under a Licensor Patent: As further consideration for Licensor’s grant of the rights and licenses to Omthera hereunder, Omthera shall pay to Licensor a royalty on aggregate annual worldwide Net Sales of all such Licensed Products by Omthera and its Affiliates and Sublicensees (but excluding Net Sales of a given Licensed Product after its applicable Royalty Term), at the percentage rates set forth below: Annual Worldwide Net Sales of Such Licensed Products per Calendar Year (US Dollars) Incremental Royalty Rate For Net Sales of such Licensed Products from [***] up to and including [***] [***]% For that portion of Net Sales of such Licensed Products that is greater than [***] [***]% By way of illustration, assume in a Calendar Year that aggregate worldwide annual Net Sales of all such Licensed Products total $[***]. The total royalties due and payable by Omthera to Licensor for such Net Sales would be $[***], calculated as follows: [***]
